
Novartis trial for breast cancer inhibitor produce 'compelling' and 'landmark' results
'Compelling and landmark' results will ‘fundamentally change’ the journey of patients with stage 2 and 3 early breast cancer, specifically those in need of new, well-tolerated options to prevent their cancer from coming back.